PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia. Kong C, Wu M, Lu Q, Ke B, et al. Leuk Res 2024;144:107548.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kong C, Wu M, Lu Q, Ke B, et al. PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia. Leuk Res 2024;144:107548.
PMID: 39018782